nach oben

Erschienen in:

04.03.2022 | Original Article

Changes of gut microbiota in diabetic nephropathy and its effect on the progression of kidney injury

verfasst von: Kedan Cai, Yanhong Ma, Fanghao Cai, Xiaohan Huang, Liang Xiao, Chenyu Zhong, Pingping Ren, Qun Luo, Jianghua Chen, Fei Han

Erschienen in: Endocrine | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We aimed to illustrate gut microbiota and short chain fatty acid (SCFA) levels in diabetic nephropathy (DN) patients, and investigate the mechanism of sodium butyrate in diabetic mellitus (DM) rats.

Methods

Gut microbiota and serum SCFA levels were measured by 16S rDNA and GC-MS. After being built by streptozotocin (DM rats), the DM rats were administered 300 mg/kg sodium butyrate for 12 weeks (DM + BU rats). Gut microbiota, serum and fecal butyrate level were measured. RT-PCR, WB and transmission electron microscopy were performed to explore LC3mRNA or LC3B protein expression, and autophagosomes in kidney tissues. AMPK/mTOR protein expression in renal tissue were also measured.

Results

The gut microbial dysbiosis was found in DM and DN groups, and some SCFAs-producing bacteria were decreased in DN group. The serum butyrate concentrations were lower in SCFA-DN group compared with SCFA-HC group and SCFA-DM group in the other cohort. Serum butyrate level was positively correlated with eGFR. Sodium butyrate increased serum and fecal butyrate levels, and improved the enlargement of glomerular area and fibronectin and collagen IV expressions in renal tissues in DM + BU rats. The LC3 mRNA, LC3BII/I ratio and number of autophagosomes were increased in renal tissue of DM + BU rats. Higher p-AMPK/AMPK ratio and lower p-mTOR/ mTOR ratio were shown in renal tissue of DM + BU rats compared with DM rats.

Conclusions

We found the decrease in SCFAs-producing bacteria and low SCFAs concentrations in DN patients. Oral butyrate supplementation may improve kidney injury in DM rats, possibly by increasing autophagy via activating AMPK/mTOR pathway.

Nur mit Berechtigung zugänglich

Y.Z. Li, T. Di, X.G. Shi et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 369, m997 (2020)PubMedPubMedCentralCrossRef

R.T. Demmer, A.M. Zuk, M. Rosenbaum, M. Desvarieux, Prevalence of diagnosed and undiagnosed type 2 diabetes mellitus among us adolescents: results from the continuous NHANES, 1999–2010. Am J Epidemiol 178(7), 1106–1113 (2013)PubMedPubMedCentralCrossRef

R.Z. Alicic, E.J. Johnson, K.R. Tuttle, SGLT2 Inhibition for the prevention and treatment of diabetic kidney disease: a review. Am J Kidney Dis 72(2), 267–277 (2018)PubMedCrossRef

R.Z. Alicic, M.T. Rooney, K.R. Tuttle, Diabetic kidney disease challenges, progress, and possibilities. Clin J Am Soc Nephrol 12(12), 2032–2045 (2017)PubMedPubMedCentralCrossRef

H.J. Anders, K. Andersen, B. Stecher, The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int 83(6), 1010–1016 (2013)PubMedCrossRef

J.J. Qin, Y.R. Li, Z.M. Cai et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 490(7418), 55–60 (2012)PubMedCrossRef

T. Høverstad, T. Midtvedt, Short-chain fatty acids in germfree Mice and Rats1. J Nutr 116(9), 1772–1776 (1986)PubMedCrossRef

S.Q. Wang, D. Lv, S.H. Jiang et al. Quantitative reduction in short-chain fatty acids, especially butyrate, contributes to the progression of chronic kidney disease. Clin Sci (Lond) 133(17), 1857–1870 (2019)CrossRef

A. Jacobson, L. Lam, M. Rajendram et al. A gut commensal-produced metabolite mediates colonization resistance to salmonella infection. Cell Host Microbe 24(2), 296–307 (2018)PubMedPubMedCentralCrossRef

10.

V. Andrade-Oliveira, M.T. Amano, M. Correa-Costa et al. Gut bacteria products prevent AKI induced by ischemia-reperfusion. J Am Soc Nephrol 26(8), 1877–1888 (2015)PubMedPubMedCentralCrossRef

11.

N. Liu, L.Q. Xu, Y.F. Shi, S.G. Zhuang, Podocyte autophagy: a potential therapeutic target to prevent the progression of diabetic nephropathy. J Diabetes Res 2017, 3560238 (2017)PubMedPubMedCentral

12.

S. Alers, A.S. Löffler, S. Wesselborg, B. Stork, Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol Cell Biol 32(1), 2–11 (2011)PubMedCrossRef

13.

W. Huang, Y. Man, C. Gao et al. Short-chain fatty acids ameliorate diabetic nephropathy via GPR43-mediated inhibition of oxidative stress and NF-κB signaling. Oxid Med Cell Longev 2020, 4074832 (2020)PubMedPubMedCentral

14.

P.H. Marathe, H.X. Gao, K.L. Close, American diabetes association standards of medical care in Diabetes 2017. J Diabetes. 9(4), 320–324 (2017)PubMedCrossRef

15.

T.K. Hansen, L. Tarnow, S. Thiel et al. Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes. 53(6), 1570–1576 (2004)PubMedCrossRef

16.

T.W. Tervaert, A.L. Mooyaart, K. Amann et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 21(4), 556–563 (2010)PubMedCrossRef

17.

Y. Sun, C. Zhou, Y. Chen, X. He, F. Gao, D. Xue, Quantitative increase in short-chain fatty acids, especially butyrate protects kidney from ischemia/reperfusion injury. J Investig Med 2020, 001715 (2021)

18.

N. Mizushima, T. Yoshimori, B. Levine, Methods in mammalian autophagy research. Cell. 140(3), 313–326 (2010)PubMedPubMedCentralCrossRef

19.

M. Hamasaki, N. Furuta, A. Matsuda et al. Autophagosomes form at ER–mitochondria contact sites. Nature. 495(7441), 389–393 (2013)PubMedCrossRef

20.

M.Y. Kim, J.H. Lim, H.H. Youn et al. Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK–SIRT1–PGC1α axis in db/db mice. Diabetologia 56(1), 204–217 (2013)PubMedCrossRef

21.

S.B. Tao, L.Z. Li, L. Li et al. Understanding the gut–kidney axis among biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls: an analysis of the gut microbiota composition. Acta Diabetol 56(5), 581–592 (2019)PubMedCrossRef

22.

Z.G. Ren, A. Li, J.W. Jiang et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 68(6), 1014–1023 (2019)PubMedCrossRef

23.

Y. Yamaguchi, K. Adachi, T. Sugiyama et al. Association of intestinal microbiota with metabolic markers and dietary habits in patients with type 2 diabetes. Digestion. 94(2), 66–72 (2016)PubMedCrossRef

24.

Q. Feng, S.S. Liang, H.J. Jia et al. Gut microbiome development along the colorectal adenoma–carcinoma sequence. Nat Commun 6, 6528 (2015)PubMedCrossRef

25.

E.B. Daliri, C.N. Tango, B.H. Lee, D.H. Oh, Human microbiome restoration and safety. Int J Med Microbiol 308(5), 487–497 (2018)PubMedCrossRef

26.

W.P. Dong, Y. Jia, X.X. Liu et al. Sodium butyrate activates NRF2 to ameliorate diabetic nephropathy possibly via inhibition of HDAC. J Endocrinol 232(1), 71–83 (2017)PubMedCrossRef

27.

Y. Du, G. Tang, W.J. Yuan, Suppression of HDAC2 by sodium butyrate alleviates apoptosis of kidney cells in db/db mice and HGinduced NRK52E cells. Int J Mol Med 45(1), 210–222 (2019)PubMedPubMedCentral

28.

Y.J. Li, X.C. Chen, T.K. Kwan et al. Dietary fiber protects against diabetic nephropathy through short-chain fatty acid–mediated activation of G protein–coupled receptors GPR43 and GPR109A. J Am Soc Nephrol 31(6), 1267–1281 (2020)PubMedPubMedCentralCrossRef

29.

Y. Li, X.H. Su, Y. Gao et al. The potential role of the gut microbiota in modulating renal function in experimental diabetic nephropathy murine models established in same environment. Biochim Biophys Acta Mol Basis Dis 1866(6), 165764 (2020)PubMedCrossRef

30.

M. Kobayashi, D. Mikami, H. Kimura et al. Short-chain fatty acids, GPR41 and GPR43 ligands, inhibit TNF-α-induced MCP-1 expression by modulating p38 and JNK signaling pathways in human renal cortical epithelial cells. Biochem Biophys Res Commun 486(2), 499–505 (2017)PubMedCrossRef

31.

J.L. Gu, W. Huang, W.Q. Zhang et al. Sodium butyrate alleviates high-glucose-induced renal glomerular endothelial cells damage via inhibiting pyroptosis. Int Immunopharmacol 75, 105832 (2019)PubMedCrossRef

32.

A.D.A. Barbosa Júnior, H. Zhou, D. HÜltenschmidt, V. Totovic, N. Jurilj, U. Pfeife, Inhibition of cellular autophagy in proximal tubular cells of the kidney in streptozotocin-diabetic and uninephrectomized rats. Virchows Arch B Cell Pathol Incl Mol Patho 61(6), 359–366 (1992)CrossRef

33.

C.M. Qiao, M.F. Sun, X.B. Jia et al. Sodium butyrate causes α-synuclein degradation by an Atg5-dependent and PI3K/Akt/mTOR-related autophagy pathway. Exp Cell Res 387(1), 111772 (2020)PubMedCrossRef

34.

J.T. Zhang, M. Yi, L.Y. Zha et al. Sodium butyrate induces endoplasmic reticulum stress and autophagy in colorectal cells: implications for apoptosis. PLoS One 11(1), e0147218 (2016)PubMedPubMedCentralCrossRef

35.

S.L. Luo, Z.Y. Li, L.Z. Mao, S.Q. Chen, S.X. Sun, Sodium butyrate induces autophagy in colorectal cancer cells through LKB1/AMPK signaling. J Physiol Biochem 75(1), 53–63 (2018)PubMedCrossRef

36.

A. Gonzalez, R. Krieg, H. Massey et al. Sodium butyrate ameliorates insulin resistance and renal failure in CKD rats by modulating intestinal permeability and mucin expression. Nephrol Dial Transplant 34(5), 783–794 (2019)PubMedCrossRef

37.

F.F. Wang, H.S. Wu, M.J. Fan et al. Sodium butyrate inhibits migration and induces AMPK‐mTOR pathway‐dependent autophagy and ROS‐mediated apoptosis via the miR‐139‐5p/Bmi‐1 axis in human bladder cancer cells. FASEB J 34(3), 4266–4282 (2020)PubMedCrossRef

38.

F. Gao, Y.W. Lv, J. Long et al. Butyrate improves the metabolic disorder and gut microbiome dysbiosis in mice induced by a high-fat diet. Front Pharmacol 10, 1040 (2019)PubMedPubMedCentralCrossRef

39.

Si X., Shang W.T., Zhou Z.K., et al. Gut microbiome-induced shift of acetate to butyrate positively manages dysbiosis in high fat diet. Mol Nutr Food Res. 62(3), (2018). https://doi.org/10.1002/mnfr.201700670

40.

N. Roshanravan, R. Mahdavi, E. Alizadeh et al. Effect of butyrate and inulin supplementation on glycemic status, lipid profile and glucagon-like peptide 1 level in patients with type 2 diabetes: a randomized double-blind, placebo-controlled trial. Horm Metab Res 49(11), 886–891 (2017)PubMedCrossRef

41.

L.L. Jia, D.Y. Li, N.H. Feng et al. Anti-diabetic effects of clostridium butyricum CGMCC0313.1 through promoting the growth of gut butyrate-producing bacteria in type 2 diabetic mice. Sci Rep 7(1), 7046 (2017)PubMedPubMedCentralCrossRef

42.

H. Yadav, J.H. Lee, J. Lloyd, P. Walter, S.G. Rane, Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem 288(35), 25088–25097 (2013)PubMedPubMedCentralCrossRef

43.

T. Jin, J.P. Weng, Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives. Am J Physiol Endocrinol Metab 311(3), 620–627 (2016)CrossRef

44.

V.A. Lizunov, J.P. Lee, M.C. Skarulis, J. Zimmerberg, S.W. Cushman, K.G. Stenkula, Impaired tethering and fusion of GLUT4 vesicles in insulin-resistant human adipose cells. Diabetes. 62(9), 3114–3119 (2013)PubMedPubMedCentralCrossRef

45.

I.P. Salt, D.G. Hardie, AMP-activated protein kinase: an ubiquitous signaling pathway with key roles in the cardiovascular system. Circ Res 120(11), 1825–1841 (2017)PubMedPubMedCentralCrossRef

Titel: Changes of gut microbiota in diabetic nephropathy and its effect on the progression of kidney injury
verfasst von: Kedan Cai
Yanhong Ma
Fanghao Cai
Xiaohan Huang
Liang Xiao
Chenyu Zhong
Pingping Ren
Qun Luo
Jianghua Chen
Fei Han
Publikationsdatum: 04.03.2022
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 2/2022
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-022-03002-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Changes of gut microbiota in diabetic nephropathy and its effect on the progression of kidney injury